Publications

• Treatment scheduling effects on the evolution of drug resistance in heterogeneous cancer cell populations.Patwardhan GA, Marczyk M, Wali VB, Stern DF, Pusztai L, Hatzis C. NPJ Breast Cancer. 2021 May 26; 2021 May 26. PMID: 34040000.
• Identifying modules of cooperating cancer drivers.Klein MI, Cannataro VL, Townsend JP, Newman S, Stern DF, Zhao H. Mol Syst Biol. 2021 Mar. PMID: 33769711.
• Acquired Resistance to HER2-Targeted Therapies Creates Vulnerability to ATP Synthase Inhibition.Gale M, Li Y, Cao J, Liu ZZ, Holmbeck MA, Zhang M, Lang SM, Wu L, Do Carmo M, Gupta S, Aoshima K, DiGiovanna MP, Stern DF, Rimm DL, Shadel GS, Chen X, Yan Q. Cancer Res. 2020 Feb 1; 2019 Nov 5. PMID: 31690671.
• Combinatorial drug screening of mammary cells with induced mesenchymal transformation to identify drug combinations for triple-negative breast cancer.Colavito SA, Platt JT, Held MA, Liu Z, Sokup R, Stern DF. Oncotarget. 2019 Aug 6; 2019 Aug 6. PMID: 31448050.
• Inhibition of isoprenylation synergizes with MAPK blockade to prevent growth in treatment-resistant melanoma, colorectal, and lung cancer.Theodosakis N, Langdon CG, Micevic G, Krykbaeva I, Means RE, Stern DF, Bosenberg MW. Pigment Cell Melanoma Res. 2019 Mar; 2018 Oct 22. PMID: 30281931.
• Keeping Tumors Out of the MAPK Fitness Zone.Stern DF. Cancer Discov. 2018 Jan. PMID: 29311225.
• p90RSK Blockade Inhibits Dual BRAF and MEK Inhibitor-Resistant Melanoma by Targeting Protein Synthesis.Theodosakis N, Micevic G, Langdon CG, Ventura A, Means R, Stern DF, Bosenberg MW. J Invest Dermatol. 2017 Oct; 2017 Jun 7. PMID: 28599981.
• GRAPE: a pathway template method to characterize tissue-specific functionality from gene expression profiles.Klein MI, Stern DF, Zhao H. BMC Bioinformatics. 2017 Jun 26; 2017 Jun 26. PMID: 28651562.
• Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor.Langdon CG, Platt JT, Means RE, Iyidogan P, Mamillapalli R, Klein M, Held MA, Lee JW, Koo JS, Hatzis C, Hochster HS, Stern DF. Mol Cancer Ther. 2017 Jun; 2017 Mar 14. PMID: 28292938.
• Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer.Wali VB, Langdon CG, Held MA, Platt JT, Patwardhan GA, Safonov A, Aktas B, Pusztai L, Stern DF, Hatzis C. Cancer Res. 2017 Jan 15; 2016 Nov 21. PMID: 27872098.
• A Computational Approach for Identifying Synergistic Drug Combinations.Gayvert KM, Aly O, Platt J, Bosenberg MW, Stern DF, Elemento O. PLoS Comput Biol. 2017 Jan; 2017 Jan 13. PMID: 28085880.
• Transcriptional Profiles from Paired Normal Samples Offer Complementary Information on Cancer Patient Survival--Evidence from TCGA Pan-Cancer Data.Huang X, Stern DF, Zhao H. Sci Rep. 2016 Feb 3; 2016 Feb 3. PMID: 26837275.
• PMCA2 regulates HER2 protein kinase localization and signaling and promotes HER2-mediated breast cancer.Jeong J, VanHouten JN, Dann P, Kim W, Sullivan C, Yu H, Liotta L, Espina V, Stern DF, Friedman PA, Wysolmerski JJ. Proc Natl Acad Sci U S A. 2016 Jan 19; 2016 Jan 4. PMID: 26729871.
• SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells.Langdon CG, Wiedemann N, Held MA, Mamillapalli R, Iyidogan P, Theodosakis N, Platt JT, Levy F, Vuagniaux G, Wang S, Bosenberg MW, Stern DF. Oncotarget. 2015 Nov 10. PMID: 26485762.
• Neuregulin-activated ERBB4 induces the SREBP-2 cholesterol biosynthetic pathway and increases low-density lipoprotein uptake.Haskins JW, Zhang S, Means RE, Kelleher JK, Cline GW, Canfrán-Duque A, Suárez Y, Stern DF. Sci Signal. 2015 Nov 3; 2015 Nov 3. PMID: 26535009.
• BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume.Theodosakis N, Held MA, Marzuka-Alcala A, Meeth KM, Micevic G, Long GV, Scolyer RA, Stern DF, Bosenberg MW. Mol Cancer Ther. 2015 Jul; 2015 May 6. PMID: 25948295.
• The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors.Langdon CG, Held MA, Platt JT, Meeth K, Iyidogan P, Mamillapalli R, Koo AB, Klein M, Liu Z, Bosenberg MW, Stern DF. Pigment Cell Melanoma Res. 2015 Jul; 2015 May 6. PMID: 25854919.
• PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets.Scortegagna M, Lau E, Zhang T, Feng Y, Sereduk C, Yin H, De SK, Meeth K, Platt JT, Langdon CG, Halaban R, Pellecchia M, Davies MA, Brown K, Stern DF, Bosenberg M, Ronai ZA. Cancer Res. 2015 Apr 1; 2015 Feb 24. PMID: 25712345.
• Overexpression of ERBB4 JM-a CYT-1 and CYT-2 isoforms in transgenic mice reveals isoform-specific roles in mammary gland development and carcinogenesis.Wali VB, Gilmore-Hebert M, Mamillapalli R, Haskins JW, Kurppa KJ, Elenius K, Booth CJ, Stern DF. Breast Cancer Res. 2014 Dec 17; 2014 Dec 17. PMID: 25516216.
• Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration.Haskins JW, Nguyen DX, Stern DF. Sci Signal. 2014 Dec 9; 2014 Dec 9. PMID: 25492965.
• Significance of glioma-associated oncogene homolog 1 (GLI1) expression in claudin-low breast cancer and crosstalk with the nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) pathway.Colavito SA, Zou MR, Yan Q, Nguyen DX, Stern DF. Breast Cancer Res. 2014 Sep 25; 2014 Sep 25. PMID: 25252859.
• Convergent and divergent cellular responses by ErbB4 isoforms in mammary epithelial cells.Wali VB, Haskins JW, Gilmore-Hebert M, Platt JT, Liu Z, Stern DF. Mol Cancer Res. 2014 Aug; 2014 May 14. PMID: 24829397.
• Comparison of HER2 and phospho-HER2 expression between biopsy and resected breast cancer specimens using a quantitative assessment method.Bai Y, Cheng H, Bordeaux J, Neumeister V, Kumar S, Rimm DL, Stern DF. PLoS One. 2013; 2013 Nov 21. PMID: 24278211.
• EGF receptor activates MET through MAPK to enhance non-small cell lung carcinoma invasion and brain metastasis.Breindel JL, Haskins JW, Cowell EP, Zhao M, Nguyen DX, Stern DF. Cancer Res. 2013 Aug 15; 2013 Jun 21. PMID: 23794705.
• MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL.Tworkoski KA, Platt JT, Bacchiocchi A, Bosenberg M, Boggon TJ, Stern DF. Pigment Cell Melanoma Res. 2013 Jul; 2013 May 21. PMID: 23617806.
• Genotype-selective combination therapies for melanoma identified by high-throughput drug screening.Held MA, Langdon CG, Platt JT, Graham-Steed T, Liu Z, Chakraborty A, Bacchiocchi A, Koo A, Haskins JW, Bosenberg MW, Stern DF. Cancer Discov. 2013 Jan; 2012 Dec 13. PMID: 23239741.
• Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, Cheng E, Davis MJ, Goh G, Choi M, Ariyan S, Narayan D, Dutton-Regester K, Capatana A, Holman EC, Bosenberg M, Sznol M, Kluger HM, Brash DE, Stern DF, Materin MA, Lo RS, Mane S, Ma S, Kidd KK, Hayward NK, Lifton RP, Schlessinger J, Boggon TJ, Halaban R. Nat Genet. 2012 Sep; 2012 Jul 29. PMID: 22842228.
• Structural mechanism of the phosphorylation-dependent dimerization of the MDC1 forkhead-associated domain.Liu J, Luo S, Zhao H, Liao J, Li J, Yang C, Xu B, Stern DF, Xu X, Ye K. Nucleic Acids Res. 2012 May; 2012 Jan 10. PMID: 22234877.
• NFBD1/MDC1 regulates Cav1 and Cav2 independently of DNA damage and p53.Wilson KA, Colavito SA, Schulz V, Wakefield PH, Sessa W, Tuck D, Stern DF. Mol Cancer Res. 2011 Jun; 2011 May 6. PMID: 21551225.
• Phosphoproteomic screen identifies potential therapeutic targets in melanoma.Tworkoski K, Singhal G, Szpakowski S, Zito CI, Bacchiocchi A, Muthusamy V, Bosenberg M, Krauthammer M, Halaban R, Stern DF. Mol Cancer Res. 2011 Jun; 2011 Apr 26. PMID: 21521745.
• "Competence" progress.Stern DF. Mol Cell. 2011 May 20. PMID: 21596307.
• EGFs and ERBBs--brief history and prospects.Stern DF. Semin Cell Dev Biol. 2010 Dec; 2010 Oct 21. PMID: 20970513.
• Interactions of ErbB4 and Kap1 connect the growth factor and DNA damage response pathways.Gilmore-Hebert M, Ramabhadran R, Stern DF. Mol Cancer Res. 2010 Oct; 2010 Sep 21. PMID: 20858735.
• Centrosomal Chk2 in DNA damage responses and cell cycle progression.Golan A, Pick E, Tsvetkov L, Nadler Y, Kluger H, Stern DF. Cell Cycle. 2010 Jul 1. PMID: 20581449.
• Deciphering protein kinase specificity through large-scale analysis of yeast phosphorylation site motifs.Mok J, Kim PM, Lam HY, Piccirillo S, Zhou X, Jeschke GR, Sheridan DL, Parker SA, Desai V, Jwa M, Cameroni E, Niu H, Good M, Remenyi A, Ma JL, Sheu YJ, Sassi HE, Sopko R, Chan CS, De Virgilio C, Hollingsworth NM, Lim WA, Stern DF, Stillman B, Andrews BJ, Gerstein MB, Snyder M, Turk BE. Sci Signal. 2010 Feb 16; 2010 Feb 16. PMID: 20159853.
• BRCTing up is hard to do.Stern DF. Mol Cell. 2009 Jan 30. PMID: 19187753.
• NFBD1/MDC1, 53BP1 and BRCA1 have both redundant and unique roles in the ATM pathway.Wilson KA, Stern DF. Cell Cycle. 2008 Nov 15; 2008 Nov 29. PMID: 19001859.
• Direct resequencing of the complete ERBB2 coding sequence reveals an absence of activating mutations in ERBB2 amplified breast cancer.Zito CI, Riches D, Kolmakova J, Simons J, Egholm M, Stern DF. Genes Chromosomes Cancer. 2008 Jul. PMID: 18418848.
• ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer.Stern DF. J Mammary Gland Biol Neoplasia. 2008 Jun; 2008 May 3. PMID: 18454306.
• Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B.DiGiovanna MP, Stern DF, Edgerton S, Broadwater G, Dressler LG, Budman DR, Henderson IC, Norton L, Liu ET, Muss HB, Berry DA, Hayes DF, Thor AD. J Clin Oncol. 2008 May 10; 2008 Apr 7. PMID: 18390970.
• Regulation of the Rad53 protein kinase in signal amplification by oligomer assembly and disassembly.Jia-Lin Ma N, Stern DF. Cell Cycle. 2008 Mar 15; 2008 Jan 8. PMID: 18239457.
• ErbB3 is required for ductal morphogenesis in the mouse mammary gland.Jackson-Fisher AJ, Bellinger G, Breindel JL, Tavassoli FA, Booth CJ, Duong JK, Stern DF. Breast Cancer Res. 2008; 2008 Nov 18. PMID: 19019207.
• Carbazole is a naturally occurring inhibitor of angiogenesis and inflammation isolated from antipsoriatic coal tar.Arbiser JL, Govindarajan B, Battle TE, Lynch R, Frank DA, Ushio-Fukai M, Perry BN, Stern DF, Bowden GT, Liu A, Klein E, Kolodziejski PJ, Eissa NT, Hossain CF, Nagle DG. J Invest Dermatol. 2006 Jun. PMID: 16614726.
• Activation of the checkpoint kinase Rad53 by the phosphatidyl inositol kinase-like kinase Mec1.Ma JL, Lee SJ, Duong JK, Stern DF. J Biol Chem. 2006 Feb 17; 2005 Dec 19. PMID: 16365046.
• Global analysis of protein phosphorylation in yeast.Ptacek J, Devgan G, Michaud G, Zhu H, Zhu X, Fasolo J, Guo H, Jona G, Breitkreutz A, Sopko R, McCartney RR, Schmidt MC, Rachidi N, Lee SJ, Mah AS, Meng L, Stark MJ, Stern DF, De Virgilio C, Tyers M, Andrews B, Gerstein M, Schweitzer B, Predki PF, Snyder M. Nature. 2005 Dec 1. PMID: 16319894.
• In situ detection of specific DNA double strand breaks using rolling circle amplification.Li J, Young CS, Lizardi PM, Stern DF. Cell Cycle. 2005 Dec; 2005 Dec 27. PMID: 16294038.
• DNA damage regulates Chk2 association with chromatin.Li J, Stern DF. J Biol Chem. 2005 Nov 11; 2005 Sep 8. PMID: 16150728.
• Neuregulin-regulated gene expression in mammary carcinoma cells.Amin DN, Tuck D, Stern DF. Exp Cell Res. 2005 Sep 10. PMID: 15963498.
• Phosphoproteomics for oncology discovery and treatment.Stern DF. Expert Opin Ther Targets. 2005 Aug. PMID: 16083347.
• The Plk1 Polo box domain mediates a cell cycle and DNA damage regulated interaction with Chk2.Tsvetkov LM, Tsekova RT, Xu X, Stern DF. Cell Cycle. 2005 Apr; 2005 Apr 9. PMID: 15876876.
• Regulation of CHK2 by DNA-dependent protein kinase.Li J, Stern DF. J Biol Chem. 2005 Mar 25; 2005 Jan 24. PMID: 15668230.
• Interaction of chromatin-associated Plk1 and Mcm7.Tsvetkov L, Stern DF. J Biol Chem. 2005 Mar 25; 2005 Jan 15. PMID: 15654075.
• Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients.DiGiovanna MP, Stern DF, Edgerton SM, Whalen SG, Moore D 2nd, Thor AD. J Clin Oncol. 2005 Feb 20. PMID: 15718311.
• Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer.Modi S, DiGiovanna MP, Lu Z, Moskowitz C, Panageas KS, Van Poznak C, Hudis CA, Norton L, Tan L, Stern DF, Carter D, Seidman AD. Cancer Invest. 2005. PMID: 16203655.
• Phosphorylation of Plk1 at S137 and T210 is inhibited in response to DNA damage.Tsvetkov L, Stern DF. Cell Cycle. 2005 Jan; 2005 Jan 5. PMID: 15611664.
• ErbB2 is required for ductal morphogenesis of the mammary gland.Jackson-Fisher AJ, Bellinger G, Ramabhadran R, Morris JK, Lee KF, Stern DF. Proc Natl Acad Sci U S A. 2004 Dec 7; 2004 Nov 29. PMID: 15569931.
• A Ddc2-Rad53 fusion protein can bypass the requirements for RAD9 and MRC1 in Rad53 activation.Lee SJ, Duong JK, Stern DF. Mol Biol Cell. 2004 Dec; 2004 Sep 29. PMID: 15456903.
• More than a marker... Phosphorylated Akt in prostate carcinoma.Stern DF. Clin Cancer Res. 2004 Oct 1. PMID: 15475426.
• Microcephalin is a DNA damage response protein involved in regulation of CHK1 and BRCA1.Xu X, Lee J, Stern DF. J Biol Chem. 2004 Aug 13; 2004 Jun 25. PMID: 15220350.
• Gene expression profiling of ErbB receptor and ligand-dependent transcription.Amin DN, Perkins AS, Stern DF. Oncogene. 2004 Feb 19. PMID: 14973552.
• Establishment of a cell-free system to study the activation of Chk2.Xu X, Stern DF. Methods Mol Biol. 2004. PMID: 15187252.
• NFBD1/MDC1 regulates ionizing radiation-induced focus formation by DNA checkpoint signaling and repair factors.Xu X, Stern DF. FASEB J. 2003 Oct. PMID: 14519663.
• Rad53 phosphorylation site clusters are important for Rad53 regulation and signaling.Lee SJ, Schwartz MF, Duong JK, Stern DF. Mol Cell Biol. 2003 Sep. PMID: 12917350.
• Neural and mammary gland defects in ErbB4 knockout mice genetically rescued from embryonic lethality.Tidcombe H, Jackson-Fisher A, Mathers K, Stern DF, Gassmann M, Golding JP. Proc Natl Acad Sci U S A. 2003 Jul 8; 2003 Jun 24. PMID: 12824469.
• FHA domain-mediated DNA checkpoint regulation of Rad53.Schwartz MF, Lee SJ, Duong JK, Eminaga S, Stern DF. Cell Cycle. 2003 Jul-Aug. PMID: 12851493.
• ErbBs in mammary development.Stern DF. Exp Cell Res. 2003 Mar 10. PMID: 12648468.
• NFBD1/KIAA0170 is a chromatin-associated protein involved in DNA damage signaling pathways.Xu X, Stern DF. J Biol Chem. 2003 Mar 7; 2002 Dec 23. PMID: 12499369.
• Polo-like kinase 1 and Chk2 interact and co-localize to centrosomes and the midbody.Tsvetkov L, Xu X, Li J, Stern DF. J Biol Chem. 2003 Mar 7; 2002 Dec 18. PMID: 12493754.
• Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ: clinicopathological correlates.DiGiovanna MP, Chu P, Davison TL, Howe CL, Carter D, Claus EB, Stern DF. Cancer Res. 2002 Nov 15. PMID: 12438265.
• Production of antibodies that recognize specific tyrosine-phosphorylated peptides.DiGiovanna MP, Stern DF, Roussel RR. Curr Protoc Immunol. 2002 Nov. PMID: 18432869.
• Chk2 activation and phosphorylation-dependent oligomerization.Xu X, Tsvetkov LM, Stern DF. Mol Cell Biol. 2002 Jun. PMID: 12024051.
• Rad9 phosphorylation sites couple Rad53 to the Saccharomyces cerevisiae DNA damage checkpoint.Schwartz MF, Duong JK, Sun Z, Morrow JS, Pradhan D, Stern DF. Mol Cell. 2002 May. PMID: 12049741.
• Production of antibodies that recognize specific tyrosine-phosphorylated peptides.DiGiovanna MP, Roussel RR, Stern DF. Curr Protoc Cell Biol. 2002 Feb. PMID: 18228399.